Recent Publications

Theis T, Ortiz GX, Logan AWJ, Claytor KE, Feng Y, Huhn WP, Blum V, Malcolmson SJ, Chekmenev EY, Wang Q, Warren WS. Direct and cost-efficient hyperpolarization of long-lived nuclear spin states on universal 15N2-diazirine molecular tags. Sci. Adv. 2016, 2 (3), e1501438.

Theis T, Truong ML, Coffey AM, Shchepin RV, Waddell KW, Shi F, Goodson BM, Warren WS, Chekmenev EY. Microtesla SABRE Enables 10% Nitrogen-15 Nuclear Spin Polarization. J. Am. Chem. Soc. 2015, 137 (4), 1404-1407.

Theis T, Truong M, Coffey AM, Chekmenev EY, Warren WS. LIGHT-SABRE enables efficient in-magnet catalytic hyperpolarization. J. Magn. Reson. 2014, 248, 23-26.

Theis T, Ledbetter MP, Kervern G, Blanchard JW, Ganssle PJ, Butler MC, Shin HD, Budker D, Pines A. Zero-field NMR enhanced by parahydrogen in reversible exchange. J. Am. Chem. Soc. 2012, 134 (9), 3987-90.

Theis T, Ganssle P, Kervern G, Knappe S, Kitching J, Ledbetter MP, Budker D, Pines A. Parahydrogen-enhanced zero-field nuclear magnetic resonance. Nat. Phys. 2011, 7 (7), 571-575.

Research


Title

In the Theis & Warren lab we develop biomolecular magnetic resonance tools to unravel the biochemical basis of metabolic disorders, such as diabetes, cancer and cardiovascular disease. The research enables in vivo, real-time tracing of important metabolites and drugs. To widen the classes of molecules used as probes, our research focuses on fundamental spin physics and technological advances for hyperpolarized magnetic resonance. We extend the signal lifetimes of hyperpolarized probes, lower the cost of hyperpolarized imaging, and generalize low-cost hyperpolarization to many molecules, metabolites and drugs. Our developments make hyperpolarized magnetic resonance into a uniquely powerful tool to visualize metabolic pathways in disease states and during treatment. By combining cost-efficient parahydrogen induced hyperpolarization with low-cost, low-field MRI we aim towards broadly available molecular imaging that can be installed in any lab or even doctor’s office. The emerging technology can serve as a platform for fast and low-cost personalized medicine. To propel these efforts we work in a highly collaborative team of researchers at Duke, Vanderbilt, SIU, Harvard, MGH, RWTH Aachen, UC Berkeley and UC San Francisco.